# A Study of NDI 1150-101 in Patients With Solid Tumors

Source: https://onco.cc/trials/nct05128487/  
OnCo record `nct05128487` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Nimbus Saturn, Inc., active and no longer recruiting.

## Summary

A Study of NDI 1150-101 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05128487 by Nimbus Saturn, Inc., with 106 participants planned, started 2021-11-05 and due to reach its primary completion in 2025-02. Interventions recorded: NDI-101150, Pembrolizumab. Conditions listed: Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05128487
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
- Sponsor: Nimbus Saturn, Inc.
- Enrolled: 106

## Sources

- ClinicalTrials.gov NCT05128487: https://clinicaltrials.gov/study/NCT05128487

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05128487.json